Table 2.
Patient and tumor baseline characteristics and locations of nodal relapses
| All patients N = 69 |
RNI N = 30 |
Tangent only N = 16 |
No RT N = 23 |
P-value | ||
|---|---|---|---|---|---|---|
|
Age Median (Range) |
49 (29–84) | 48.5 (30–76) | 52 (35–75) | 48 (29–84) | 0.45 | |
| Laterality | Right | 34 (49%) | 14 (47%) | 8 (50%) | 12 (52%) | 0.92 |
| Left | 35 (51%) | 16 (53%) | 8 (50%) | 11 (48%) | ||
| Grade | 1 | 6 (9%) | 1 (3%) | 1 (6%) | 4 (17%) | 0.27 |
| 2 | 27 (39%) | 11 (37%) | 8 (50%) | 8 (35%) | ||
| 3 | 32 (46%) | 17 (57%) | 6 (38%) | 9 (40%) | ||
| Unknown | 4 (4%) | 1 (3%) | 1 ((6%) | 2 (9%) | ||
| Tumor size | 0-2 cm | 32 (46%) | 10 (33%) | 11 (69%) | 11 (48%) | 0.03 |
| > 2–5 cm | 26 (38%) | 12 (40%) | 5 (31%) | 9 (40%) | ||
| > 5 cm | 9 (14%) | 8 (27%) | 0 (0%) | 1 (4%) | ||
| Unknown | 2 (3%) | 0 (0%) | 0 (0%) | 2 (9%) | ||
| Number of positive nodes | 0 | 32 (46%) | 5 (17%) | 14 (88%) | 13 (57%) | < 0.01 |
| 1–3 | 19 (28%) | 13 (43%) | 2 (12%) | 4 (17%) | ||
| ≥ 4 | 14 (20%) | 11 (37%) | 0 (0%) | 3 (13%) | ||
| Unknown | 4 (6%) | 1 (3%) | 0 (0%) | 3 (13%) | ||
| Stage | I | 24 (35%) | 6 (20%) | 6 (38%) | 12 (52%) | < 0.01 |
| II | 28(40%) | 16 (54%) | 6 (38%) | 6 (26%) | ||
| III | 6(9%) | 4 (13%) | 0 (0%) | 2 (9%) | ||
| Unknown | 11(16%) | 4 (13%) | 4 (24%) | 3 (13%) | ||
| Her2 status | Positive | 6 (9%) | 4 (13%) | 1 (6%) | 1 (4%) | 0.54 |
| Negative | 40 (58%) | 19(63%) | 9 (56%) | 12 (52%) | ||
| Unknown | 23 (33%) | 7 (23%) | 6 (38%) | 10 (44%) | ||
| Estrogen status | Positive | 47 (68%) | 17 (57%) | 12 (75%) | 18 (78%) | 0.11 |
| Negative | 20 (29%) | 13 (43%) | 3 (19%) | 4 (17%) | ||
| Unknown | 2 (3%) | 0 (0%) | 1 (6%) | 1 (4%) | ||
| Surgery | BCS | 31 (45%) | 10 (33%) | 13 (81%) | 8 (35%) | < 0.01 |
| Mastectomy | 38 (55%) | 20 (66%) | 3 (19%) | 15 (65%) | ||
| Axillary lymph node dissection | Yes | 53 (77%) | 27 (90%) | 12 (75%) | 14 (61%) | 0.04 |
| No | 16 (23%) | 3 (10%) | 4 (25%) | 9 (31%) | ||
| Chemotherapy | Yes | 46 (67%) | 23 (77%) | 12 (75%) | 11 (48%) | 0.07 |
| No | 23 (33%) | 7 (23%) | 4 (25%) | 12 (52%) | ||
| Hormone therapy | Yes | 41 (59%) | 16 (53%) | 12 (75%) | 13 (57%) | 0.14 |
| No | 28(41%) | 14 (47%) | 4 (25%) | 10 (43%) | ||
|
Isolated RNR RNR and distant metastases |
31 (45%) | 9 (30%) | 9 (56%) | 13 (57%) | 0.09 | |
| 38 (55%) | 21 (70%) | 7 (44%) | 10 (43%) | |||
| Number of RNR | 226 | 92 | 48 | 86 | ||
| RNR per Patient | 3.3 | 3.1 | 3.0 | 3.7 | 0.28 | |
| RNR Locations |
SCF (CTV4) |
35 | 20 | 7 | 8 | |
| (ESTRO CTV) | Axilla Level 1 (CTV1) | 64 | 22 | 15 | 27 | |
| Axilla Level 2 (CTV2) | 27 | 7 | 8 | 12 | ||
| Interpectoral | 11 | 5 | 1 | 5 | ||
| Axilla Level 3 (CTV3) | 34 | 12 | 6 | 16 | ||
| IMN | 34 | 18 | 7 | 9 | ||
|
RADCOMP Posterior Neck |
21 | 8 | 4 | 9 |
Abbreviation: RNR Regional nodal recurrence